GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (NYSE:HLN) » Definitions » COGS-to-Revenue

Haleon (Haleon) COGS-to-Revenue : 0.37 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Haleon COGS-to-Revenue?

Haleon's Cost of Goods Sold for the three months ended in Mar. 2024 was $1,374 Mil. Its Revenue for the three months ended in Mar. 2024 was $3,709 Mil.

Haleon's COGS to Revenue for the three months ended in Mar. 2024 was 0.37.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Haleon's Gross Margin % for the three months ended in Mar. 2024 was 62.97%.


Haleon COGS-to-Revenue Historical Data

The historical data trend for Haleon's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon COGS-to-Revenue Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.43 0.40 0.38 0.39 0.40

Haleon Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.38 0.39 0.46 0.37

Haleon COGS-to-Revenue Calculation

Haleon's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=5765.823 / 14306.329
=0.40

Haleon's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1373.571 / 3709.022
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haleon  (NYSE:HLN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Haleon's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1373.571 / 3709.022
=62.97 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Haleon COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Haleon's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Haleon (Haleon) Business Description

Traded in Other Exchanges
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.